Managers / Q4 2022 · view latest →
Brown University
CIK 0001664741 · ONE CITIZENS PLAZA, 4TH FLOOR SUITE 410, PROVIDENCE, RI, 02903 · 4018673998
Reported Value
Under review
reported total failed a data-quality check
Positions
5
Filings on Record
26
2019–present window
Filed
Jan 24, 2023
original filing
Summary
Compared with Q3 2022, the fund opened 1 new position and exited 2.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 96.1% · $230,015
- Other · 3.7% · $8,771
- ADR · 0.2% · $584
Quarter-over-Quarter Changes full breakdown →
vs Q3 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PROKIDNEY CORP | NEW | +1.00M | 1.00M | +$6,860 | $6,860 |
| AMZNAMAZON COM INC | SOLD OUT | −165.8K | 0 | −$19M | $0 |
| ROYALTY PHARMA PLC | SOLD OUT | −331.8K | 0 | −$13M | $0 |
| OWLBLUE OWL CAPITAL INC | TRIMMED | −989.1K | 14.79M | −$146M | $156,803 |
| OBDCOWL ROCK CAPITAL CORPORATION | HELD | +0 | 6.34M | −$66M | $73,212 |
| ATAI LIFE SCIENCES NV | HELD | +0 | 718.5K | −$2M | $1,911 |
| CMPSCOMPASS PATHWAYS PLC | HELD | +0 | 72.7K | −$779,416 | $584 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2022
5 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | OWLBLUE OWL CAPITAL INChistory → | COM CL A | 65.51% | $156,803 | 14.79M |
| 2 | OBDCOWL ROCK CAPITAL CORPORATIONhistory → | COM | 30.59% | $73,212 | 6.34M |
| 3 | PROKIDNEY CORP | CLASS A ORD SHS | 2.87% | $6,860 | 1.00M |
| 4 | ATAI LIFE SCIENCES NV | SHS | 0.80% | $1,911 | 718.5K |
| 5 | CMPSCOMPASS PATHWAYS PLC | SPONSORED ADS | 0.24% | $584 | 72.7K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $102M | 11 | May 1, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $143M | 10 | Jan 30, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $169M | 8 | Nov 5, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $142M | 9 | Aug 8, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $216M | 14 | May 2, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $235M | 12 | Feb 10, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $247M | 10 | Nov 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $265M | 10 | Jul 26, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $251M | 10 | May 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $277M | 8 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $250M | 7 | Oct 17, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $269M | 6 | Aug 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | Under review | 7 | May 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 5 | Jan 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $247M | 6 | Nov 3, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $336M | 13 | Jul 29, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $409M | 13 | May 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $410M | 8 | Jan 28, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $738M | 8 | Oct 25, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $604M | 6 | Jul 30, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $146M | 5 | May 5, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $138M | 7 | Feb 8, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $141M | 6 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $136M | 6 | Jul 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $115M | 5 | Apr 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $184M | 11 | Jan 22, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.